Integra LifeSciences Holdings Corporation (NASDAQ:IART – Get Free Report) has been given an average rating of “Reduce” by the six ratings firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating and four have assigned a hold rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $14.00.
A number of brokerages have issued reports on IART. Wall Street Zen upgraded shares of Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Wells Fargo & Company increased their price objective on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and increased their price objective for the stock from $11.00 to $16.00 in a research note on Thursday, May 28th. Finally, Truist Financial reduced their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th.
View Our Latest Stock Analysis on IART
Institutional Investors Weigh In On Integra LifeSciences
Integra LifeSciences Trading Up 1.4%
IART stock opened at $17.71 on Wednesday. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38. The company’s 50-day simple moving average is $13.60 and its 200 day simple moving average is $12.26. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $18.19. The company has a market capitalization of $1.38 billion, a PE ratio of -2.74, a price-to-earnings-growth ratio of 1.21 and a beta of 1.24.
Integra LifeSciences (NASDAQ:IART – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. The firm had revenue of $391.92 million for the quarter, compared to the consensus estimate of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The business’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, sell-side analysts anticipate that Integra LifeSciences will post 2.44 earnings per share for the current year.
Integra LifeSciences Company Profile
Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.
Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.
Read More
- Five stocks we like better than Integra LifeSciences
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
